Floatz logo

LEUPROLIDE

CDK4/6 Inhibitor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milanoprotein_peptideActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the CDK4/6 Inhibitor cohort.

Asset / SponsorPhaseRating
Letrozole
Fujian Cancer Hospital
Phase 2CCC
TAMOXIFEN
Fujian Cancer Hospital
Phase 2CCC
Arimidex
Fujian Cancer Hospital
Phase 2CCC
EXEMESTANE
Fujian Cancer Hospital
Phase 2CCC
DALPICICLIB ISETIONATE
Fujian Cancer Hospital
Phase 2CCC

View all 10 →

Same molecule, other indications

LEUPROLIDE is also rated in:

prostate carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
metastatic prostate carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →